Development of Cell-Based Functional Assays to Accelerate Commercialization and Therapeutic Application of Recombinant Antibodies

Antibodies are used for treatment of many diseases, including cancer. Within the human immune system, antibodies fight invading bacteria and viruses. We have devised a way to make high-quality antibodies in the laboratory and target them to specific disease-related proteins that have been identified by the scientific community and in our lab. Ensuring that these antibodies work in cells the way we intend them to in the body is a critical step of identifying their potential as therapeutic agents and also in the commercialization process. The proposed research project involves testing our synthetic antibodies against disease-associated targets; antibodies showing clinical relevancy will be considered for entry into the clinical trial pipeline. The partner for this application, the newly formed Centre for the Commercialization of Antibodies and Biologics (CCAB), will bridge this basic research and discovery with clinician scientists and industry partners to enable accelerated delivery of new therapies.

Bradley Yates
Faculty Supervisor: 
Jason Moffat
Partner University: